A Study of Sacituzumab Govitecan in People With Mesothelioma

This study tests sacituzumab govitecan — an antibody-drug therapy that targets cancer cells and delivers chemotherapy directly to them — in patients with pleural mesothelioma, a rare cancer of the lung lining often linked to asbestos exposure. **You may be eligible if...** - You are 18 or older - You have been confirmed to have diffuse pleural mesothelioma - You have already received at least one prior treatment (including a platinum-based therapy) - Your overall health is adequate to tolerate treatment **You may NOT be eligible if...** - You have never received prior systemic treatment - Your organ function is too impaired to handle the drug safely - You have certain other serious medical conditions Talk to your doctor to see if this trial is right for you.